A deep dive into ALKEM (ALKEM) — examining the financials, valuation picture, and who owns the stock.
Alkem Lab Revenue Trend
Revenue rose 3.7% to ₹13,458 Cr in FY2025 for ALKEM, against ₹12,978 Cr the year before.
Revenue compounded at 13.7% annually over 10 years for ALKEM. That's a strong growth rate that comfortably outpaces inflation.
ALKEM is a major pharmaceuticals company by revenue, with a top line of ₹13,458 Cr.
It's been 10 years of continuous revenue growth for ALKEM — a pattern worth noting.
| Year | Revenue | YoY % |
|---|---|---|
| FY2025 | ₹13,458 Cr | +3.7% |
| FY2024 | ₹12,978 Cr | +9.8% |
| FY2023 | ₹11,815 Cr | +9.4% |
| FY2022 | ₹10,797 Cr | +18.7% |
| FY2021 | ₹9,098 Cr | — |
View ALKEM's full 10-year revenue trend with CAGR analysis →
Alkem Lab Profitability
Profitability strengthened with net income of ₹2,215 Cr in FY2025, 22.3% higher than FY2024.
Cost discipline paid off, with net profit margin expanding to 16.5% from 14.0%.
On a per-share basis, diluted earnings were ₹181.11 in FY2025 versus ₹150.19 in FY2024.
Is Alkem Lab Undervalued
ALKEM shares are currently trading at ₹5,707.00.
Craytheon calculates intrinsic value using the P/E Ratio, DCF, and EPS Growth models. All three appear in the Valuation Models cards below.
Valuation Models
Alkem Lab Shareholding Pattern
Promoters trimmed their stake from 51.2% to 49.7% over the last 4 quarters.
FII holding stands at 10.4%, up from 9.5% in the year-ago quarter.
Domestic institutional investors (DIIs) held 22.6% as of June 2026, up from 21.9% a year ago.
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Jun 2026 | 49.7% | 10.4% | 22.6% | 17.2% |
| Mar 2026 | 51.2% | 10.2% | 21.4% | 17.2% |
| Dec 2025 | 51.2% | 10.0% | 21.5% | 17.3% |
| Sep 2025 | 51.2% | 9.5% | 21.9% | 17.4% |
Track quarterly shareholding changes for ALKEM →
Alkem Lab Balance Sheet
Proportional view as of 3 Aug 2026. Hover blocks for details.
Assets
Liabilities & Equity
FY2025 total assets: ₹176.91B (up 13.6% YoY from ₹155.75B).
Top categories: Other Assets (40.4%), Inventories (16.5%), Property, Plant & Equipment (14.4%).
Of the ₹176.91B in liabilities and equity, 70.3% is shareholder equity, 7.8% is interest-bearing debt, and 21.9% is operating liabilities. Over the year, debt is down 2.6% and equity is up 16.0%.
Balance sheet composition — FY 2025
| Category | Value |
|---|---|
| Cash & ST Investments | 12.06B |
| Receivables | 24.66B |
| Inventories | 29.22B |
| Property, Plant & Equipment | 25.40B |
| Investments | 9.43B |
| Intangibles & Goodwill | 4.66B |
| Other Assets | 71.46B |
| Category | Value |
|---|---|
| Equity | 124.34B |
| Short-term Debt | 8.03B |
| Long-term Debt | 5.78B |
| Trade Payables | 18.39B |
| Other Liabilities | 20.37B |
Alkem Lab Key Takeaways
In summary, ALKEM (ALKEM) presents the following picture for fundamental analysts.
Revenue of ₹13,458 Cr in FY2025, up 3.7% year-over-year.
Long-term revenue has been compounding at 13.7% annually over 10 years.
The company is profitable, with a net margin of 16.5% and net income of ₹2,215 Cr.
Unlock Full Analysis
For the complete 10-year financial history with interactive charts and growth analysis, explore ALKEM's detailed profile on Craytheon.